PTGS2 and colorectal carcinoma: The proportions of having at least one prescription in the prior 5 years for selective COX-2 inhibitors were not significantly different (p=0.595); however, the average cumulative defined daily dose (DDD) differed significantly between CRC patients and controls (78.0±151.1 vs. 85.5±120.5, p=0.010).